Among people living with amyotrophic lateral sclerosis (ALS), requests to be referred for medical assistance in dying, known as MAiD, may have more to do with individual preferences about life-sustaining interventions than disease severity. That’s according to a new Canadian study showing that people with ALS using noninvasive…
News
Enrollment of adults with mild-to-moderate amyotrophic lateral sclerosis (ALS) has been completed in a clinical trial testing PHENOGENE-1A as an add-on treatment for the neurodegenerative disease. Enrollment of about 105 participants in the Phase 2b trial (NCT07142291) wrapped up in late August, and they were randomly assigned to…
Nearly 500 people gathered in Orlando, Florida, and more than 1,900 joined them online to discuss advances in amyotrophic lateral sclerosis (ALS) research and care and community goals for the future at the third annual ALS Nexus Conference. Clinicians, researchers, patients, caregivers, advocates, industry partners, and others in the…
People with amyotrophic lateral sclerosis (ALS) who are exposed to high levels of certain pollutants in the years before disease onset have worse survival outcomes, a new study shows. The findings add to building evidence that pollution and environmental toxins can affect the course of ALS. Researchers are calling…
A buildup of microplastics in the nervous system may be linked to a higher risk of developing amyotrophic lateral sclerosis (ALS), according to a new study. People newly diagnosed with the neurodegenerative disease were found to have higher concentrations of tiny plastic particles in both their blood and the…
A newer set of diagnostic criteria for amyotrophic lateral sclerosis (ALS) was significantly more sensitive at identifying people with the disease than two older diagnostic approaches, a real-world study in Germany found. Among more than 400 people ultimately diagnosed with ALS, these Gold Coast criteria correctly identified 92.5% of…
Neurosense Therapeutics is revamping its development plan for PrimeC, the company’s experimental oral therapy for amyotrophic lateral sclerosis (ALS). The updated plan includes a new study that will directly compare PrimeC against an approved ALS treatment, as well as a restructured Phase 3 trial and analyses of…
BTT Medical Institute is launching an early-stage clinical trial to test the safety of the Abreu BTT 700 Temperature Management System — a device that slowly raises body temperature to induce a controlled fever — with the goal of developing it as a possible treatment for amyotrophic lateral…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to CK0803, an experimental T-cell therapy from Cellenkos that’s currently in Phase 1 clinical testing for people with amyotrophic lateral sclerosis (ALS). The designation aims to accelerate the clinical development and regulatory review of new treatments that…
ALN-SOD, an experimental RNA-based therapy being developed for a genetic subtype of amyotrophic lateral sclerosis (ALS) called SOD1-ALS, showed an “encouraging” safety profile and preliminary signs of potential efficacy, according to early results from a Phase 1b/2 study. Biomarker data from participants in the first-in-human Phase 1b/2 GOALS…
Recent Posts
- Personal preferences key to medically assisted death requests in ALS
- Being an ALS caregiver was as hard emotionally as it was physically
- Finding moments that transcend the grief of ALS
- Enrollment complete in Phase 2b trial of add-on therapy for adults with ALS
- ALS Nexus 2026: Event spotlights care advances, community goals